As part of the marketing procedure for the inactivated tetravalent influenza vaccine FluarixTetra®, the French High Council of public health (HCSP) has issued recommendations to determine this vaccine's place in the current immunisation strategy for preventing seasonal influenza.
FluarixTetra® is an inactivated split virion influenza vaccine containing two influenza A virus sub-types (H1N1 and H3N2) and two types of influenza B viruses (Victorian and Yamagata lineages).
The HCSP has taken into account national and international epidemiological data relating to seasonal influenza B, and the immunogenicity and tolerance data for this vaccine.
It considers that the FluarixTetra® vaccine can be used in accordance with its current marketing authorisation (from 3 years of age) and as part of the French immunisation strategy against seasonal influenza which aims to prevent serious forms of the disease and deaths.
However, based on current epidemiology and virology data available to date in France, and in the absence of any clinical efficacy data, there are no elements pointing to the preferred use of the FluarixTetra® vaccine compared to the inactivated trivalent vaccines, nor to the identification of one or more populations in which this vaccine could be recommended preferentially.
- Recommendation
- Europe
- France
- Influenza
